Altered plasma albumin characteristics and lymphocyte populations in gastrointestinal cancer patients: Detection using modified fluorescence responses

Figures & data

Figure 1.  Chemical structure of the ABM fluorescent probe. In the structure, X = a morpholino substitution at the site indicated on the ring.

Figure 2.  ABM fluorescence intensity in lymphocytes and in plasma from “Common group” patients. Gastrointestinal cancer patients (colorectal cancer, Stage II+III + gastric cancer, Stage III); “Common group” (n = 26). Group number in figure is used to reflect from whom/when samples were isolated [i.e., Group 1: pre-surgery; Group 2: post-surgery; and Group 3: from healthy donors (control group; n = 14)]. Solid bar in each set: ABM fluorescence in lymphocytes; hatched bar in each set: ABM fluorescence in plasma. All intensity values are shown in AU (arbitrary units; mean ± SE). At P < 0.05, *value significantly different from pre-surgical value and/or ^#significantly different from control group value.

Figure 3.  ABM fluorescence intensity in lymphocytes and in plasma from “Colorectal group” patients. Colorectal cancer patients only (Stage II–III) (n = 10). Group number in figure is used to reflect from whom/when samples were isolated [i.e., Group 1: pre-surgery; Group 2: post-surgery; and Group 3: from healthy donors (control group; n = 14)]. Solid bar in each set: ABM fluorescence in lymphocytes; hatched bar in each set: ABM fluorescence in plasma. All intensity values are shown in AU (arbitrary units; mean ± SE). At P < 0.05, *value significantly different from pre-surgical value and/or ^#significantly different from control group value.

Figure 4.  ABM fluorescence intensity in lymphocytes and in plasma from “Gastric group” patients. Gastric cancer patients only (Stage III) (n = 10). Group number in figure is used to reflect from whom/when samples were isolated [i.e., Group 1: pre-surgery; Group 2: post-surgery; and Group 3: from healthy donors (control group; n = 14)]. Solid bar in each set: ABM fluorescence in lymphocytes; hatched bar in each set: ABM fluorescence in plasma. All intensity values are shown in AU (arbitrary units; mean ± SE). At P < 0.05, *value significantly different from pre-surgical value and/or ^#significantly different from control group value.

Table 1.  Peripheral blood lymphocyte subpopulation counts in gastrointestinal cancer patients (i.e., “Common group”).

Gastrointestinal cancer patients (colorectal cancer, Stage II+III + gastric cancer, Stage III); “Common group” (n=26)
	Lymphocytes (%)	^aCD3^+	CD16^+%	^aCD16^+	CD38^+%	CD4^+:CD8^+
^b1	26.80 ± 2.01	^‡1116.21 ± 119.20	13.48 ± 3.01	280.41 ± 30.12	^‡5.04 ± 0.97	^‡1.36 ± 0.07
2	*^‡20.33 ± 1.47	*^‡1063.77 ± 113.62	*7.76 ± 1.09	*132.14 ± 21.08	*^‡10.68 ± 2.06	*^‡1.55 ± 0.10
3 (Controls)	28.00 ± 1.30	1324.79 ± 115.41	12.50 ± 1.10	389.00 ± 24.11	24.60 ± 1.60	1.88 ± 0.16

^aValues shown are in terms of absolute numbers (mean ± SE).

^bIndicates when or from whom samples were isolated: (1) before surgical treatment; (2) after surgical treatment; and (3) healthy donors (control group; n = 14).

*Value significantly different from pre-surgical value (P < 0.05); ^‡significantly different from control group value (P < 0.05).

Table 2.  Peripheral blood lymphocyte subpopulation counts in the distinct subsets of the study’s cancer patients.

Colorectal cancer patients only (Stage II–III) (n=10)
	CD16^+%	^aCD16^+	CD4^+:CD8^+	CD38^+%	Lymphocytes (%)
^b1	^‡15.95 ± 2.18	^‡314.18 ± 39.27	^‡1.27 ± 0.10	^‡3.40 ± 1.20	28.00 ± 1.30
2	*^‡7.93 ± 1.43	*^‡144.75 ± 22.44	*^‡1.50 ± 0.13	*^‡12.70 ± 3.40	*^‡23.50 ± 2.20
3 (Controls)	12.50 ± 1.10	389.00 ± 24.11	1.88 ± 0.16	24.60 ± 1.60	28.00 ± 1.3
Gastric cancer patients only (Stage III) (n=10)
^b1			^‡1.27 ± 0.10	^‡15.30 ± 0.80	^‡32.80 ± 2.85
2			*^‡1.55 ± 0.13	*^‡17.60 ± 1.60	*^‡21.96 ± 1.60
3 (Controls)			1.88 ± 0.16	24.60 ± 1.60	28.00 ± 1.30

^aValues shown are in terms of absolute numbers (mean ± SE).

^bIndicates when or from whom samples were isolated: (1) before surgical treatment; (2) after surgical treatment; and (3) healthy donors (control group; n = 14).

*Value significantly different from pre-surgical value (P < 0.05); ^‡significantly different from control group value (P < 0.05).